Xalatamax eye drops 0.005%, 2.5ml 3pcs

Composition

Active ingredient:

latanoprost – 0.050 mg.

Auxiliary substances:

benzalkonium chloride-0.20 mg;

sodium dihydrogen phosphate monohydrate-4.60 mg;

sodium hydrophosphate-4.74 mg;

sodium chloride-4.10 mg;

purified water-996.31 mg

Pharmacological action

Anti-glaucoma drug for topical application. Latanoprost is an analog_{of prostaglandin f2a} and a selective agonist of FP receptors.

Reduces intraocular pressure by increasing the outflow of watery moisture and has an anti-glaucoma effect. The main mechanism of action of latanoprost is associated with an increase in uveoscleral outflow.

It has no significant effect on the production of aqueous humor and does not affect the hemato-ophthalmic barrier.

A decrease in intraocular pressure begins 3-4 hours after use of the drug, the maximum effect is noted in 8-12 hours, the duration of action is at least 24 hours.

Indications

Reduction of elevated intraocular pressure (IOP) in adults and children (over the age of 1 year) with open-angle glaucoma or increased ophthalmotonus.

Use during pregnancy and lactation

Use during pregnancy is contraindicated. If it is necessary to use the drug, breastfeeding should be discontinued. No effect of latanoprost on male and female fertility was found in animal studies.

Contraindications

• Hypersensitivity to latanoprost or other components of the drug.
• Age up to 1 year (efficacy and safety have not been established).

Side effects

From the side of the visual organ:

Eye irritation (burning sensation, sand sensation in the eyes, itching, tingling and foreign body sensation), blepharitis, conjunctival hyperemia, eye pain, increased iris pigmentation, transient point erosion of the epithelium, eyelid edema, corneal edema and erosion, conjunctivitis, elongation, thickening, increased number and pigmentation of eyelashes and downy hair, iritis/uveitis, keratitis, macular edema (including cystoid edema). ), changes in the direction of eyelash growth, sometimes causing eye irritation, blurred vision. Anchor: #Dermatologicheskie_reakcii

Dermatological reactions: Rash, darkening of the skin of the eyelids and local skin reactions from the eyelids.

Nervous system disorders: Dizziness, headache.

From the respiratory system: Bronchial asthma (including acute attacks or exacerbation of the disease in patients with a history of bronchial asthma), shortness of breath.

From the musculoskeletal system: Muscle pain, joint pain.

Other: Non-specific chest pain.

Interaction

Latanoprost has an additive effect in reducing intraocular pressure when used in combination with beta-blockers, adrenomimetics, carbonic anhydrase inhibitors and a partial additive effect when used in combination with m-cholinomimetics.

In vitro studies have shown that when mixed with latanoprost eye drops containing thiomersal, precipitation occurs. Therefore, eye drops containing these substances should be applied at intervals of at least 5 minutes. Simultaneous use of 2 prostaglandin analogues can cause a paradoxical increase in intraocular pressure.

How to take, course of use and dosage

The drug is instilled into the conjunctival sac of the eyes 1 drop 1 time a day in the evening.

If a dose is missed, the next dose is administered as usual (i. e., the dose is not doubled).

With more frequent use of the drug, its effectiveness decreases.

The duration of the course of treatment and the possibility of its repetition are determined by the doctor.

Overdose

Symptoms: irritation of the eye mucosa, hyperemia of the conjunctiva or episclera.

Treatment: perform symptomatic therapy.

Description

Eye drops 0.005% transparent, colorless.

Special instructions

Latanoprost can cause a gradual change in eye color due to an increase in the amount of brown pigment in the iris.

This effect is detected mainly in patients with mixed color of the iris, for example, blue-brown, gray-brown, green-brown or yellow-brown, which is explained by an increase in the content of melanin in the stromal melanocytes of the iris.

Usually, brown pigmentation spreads concentrically around the pupil to the periphery of the iris, and the entire iris or parts of it may turn a more intense brown color. In patients with evenly colored blue, gray, green or brown eyes, changes in eye color after two years of using the drug were very rare.

The color change is not accompanied by any clinical symptoms or pathological changes.

After discontinuation of the drug, there was no further increase in the amount of brown pigment, but the color change that has already developed may be irreversible. In the presence of nevi or lentigo on the iris, their changes were not noted under the influence of therapy.

Storage conditions

Store in a dry place protected from light at a temperature of 2 to 8 ° C. Store the open bottle at a temperature not exceeding 25 ° C.

Shelf life

1 year

Active ingredient

Latanoprost

Conditions of release from pharmacies

By prescription

Dosage form

eye drops